A single biopsy can represent months of coordination, clinical decision-making and patient trust. In many areas of cancer and disease research, a small piece of tissue or bodily fluid may be the only ...

The biopharmaceutical industry currently finds itself at a precarious intersection of unprecedented innovation and antiquated validation. We have unlocked unprecedented capabilities in gene editing ...

Pharmaceutical supply chains are no strangers to disruption – but recent events have added a new layer of uncertainty. A US Supreme Court ruling overturning tariffs imposed under emergency powers has ...

I often describe regulatory strategy as the invisible skeleton of a biotechnology company. When it is well-formed, you hardly notice it is there, yet it provides the essential structure that allows ...

Produced in partnership with IBTV, our Roving Reporter series captures real-time perspectives from across the life sciences industry. Filmed on the ground at Meeting on the Mesa, this episode brings ...

An off-the-shelf CAR-T cell therapy developed by researchers at WashU Medicine has been granted FDA Breakthrough Therapy designation for relapsed or refractory T-cell acute lymphoblastic leukemia and ...

An experimental gene-editing therapy has shown striking early results in people with severe sickle cell disease. In a phase 1-2 study, renizgamglogene autogedtemcel, or reni-cel, used CRISPR-Cas12a to ...

AstraZeneca is expanding its cell therapy footprint in China with plans for a commercial manufacturing and supply base in Shanghai, alongside a new innovation center focused on cell therapy R&D and ...

Cutting carbon in pharmaceutical supply chains may depend less on how much a process emits – and more on where it sits in the network. A new study shows that structurally central players, such as ...

Artificial intelligence-enabled self-driving laboratories in bioprocess engineering are most likely to develop as hybrid systems that integrate automated decision-making with sustained human oversight ...

When planning a long journey in a navigation app, you enter the final destination first and let the system calculate the best route backward. In antibody-drug conjugate (ADC) development, the field ...

Biology may be complex, but in 2025 the industry proved it doesn’t have to be chaotic. From manufacturing CAR-T cells inside the patient to industrializing organoid platforms, the year marked a ...